GlassScriptPhysician profile
Wendy Martinez
NPI 1720211527
$2,443.63
in general payments reported to CMS, 2019-2025
23 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $299 · 2023: $152 · 2024: $593 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $620.28 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $248.55 | 2022-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $236.62 | 2021-2025 | |
| Amgen INC. | $190.33 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $187.19 | 2022-2025 | Dupixent |
| Insmed, INC. | $174.14 | 2021-2025 | Arikayce |
| Harmony Biosciences LLC | $170.30 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.32 | 2022-2024 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.26 | 2022-2025 | Ofev |
| La Jolla Pharmaceutical Company | $63.32 | 2024 | Giapreza |
| Merck Sharp & Dohme LLC | $50.96 | 2023 | Zerbaxa, Dificid, Recarbrio |
| Baxter Healthcare | $47.69 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Verona Pharma, INC. | $47.49 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $43.92 | 2021-2025 | Nuzyra |
| Mallinckrodt Hospital Products INC. | $26.39 | 2025 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25.57 | 2022 | |
| Movair INC | $24.60 | 2025 | Luisa |
| Avadel Cns Pharmaceuticals, LLC | $21.57 | 2024 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $20.38 | 2025 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $17.54 | 2025 | Inspire |
| Mylan Specialty L.P. | $16.43 | 2021 | |
| Fisher & Paykel Healthcare INC | $15.13 | 2022 | |
| Vapotherm INC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.